{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CZP+200+mg+Q2W", "query": { "intervention": "CZP 200 mg Q2W" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T21:00:28.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01521923", "title": "A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol + Methotrexate (MTX)", "type": "BIOLOGICAL" }, { "name": "Placebo + Methotrexate (MTX)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 359, "start_date": "2012-01", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521923" }, { "nct_id": "NCT02552212", "title": "Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis", "Nonradiographic Axial Spondyloarthritis", "Nr-axSpA" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2015-09", "completion_date": "2020-05", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552212" }, { "nct_id": "NCT01087788", "title": "Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087788" }, { "nct_id": "NCT01550003", "title": "Pediatric Arthritis Study of Certolizumab Pegol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyarticular-course Juvenile Idiopathic Arthritis (JIA)" ], "interventions": [ { "name": "Certolizumab Pegol (CZP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 193, "start_date": "2012-03-08", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01550003" }, { "nct_id": "NCT02346240", "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2015-02-11", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 19, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346240" }, { "nct_id": "NCT01087762", "title": "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondyloarthropathies" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087762" }, { "nct_id": "NCT02505542", "title": "Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthrithis", "Ankylosing Spondylitis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 736, "start_date": "2015-07", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 16, "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02505542" }, { "nct_id": "NCT02326272", "title": "A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2014-12-15", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326272" }, { "nct_id": "NCT03357471", "title": "Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate and Severe Active Rheumatoid Arthritis", "Active Psoriatic Arthritis", "Active Ankylosing Spondylitis", "Moderately to Severely Active Crohn's Disease" ], "interventions": [ { "name": "e-Device", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-11-03", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 22, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03357471" }, { "nct_id": "NCT02326298", "title": "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2014-12-16", "completion_date": "2018-10-24", "has_results": true, "last_update_posted_date": "2019-11-07", "last_synced_at": "2026-09-16T21:00:28.629Z", "location_count": 8, "location_summary": "San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "West Des Moines", "state": "Iowa" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326298" } ] }